Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing
复制标题
DOI：
10.1038/clpt.2011.355
复制
发表时间：
2012-04-01
影响因子：
6.7
通讯作者：
Kroetz, D. L.
中科院分区：
文献类型：
--
作者：
Martin, M. A.;Klein, T. E.;Kroetz, D. L.
人类白细胞抗原B（HLA-B）是一种向免疫细胞呈递多肽的抗原，在机体对病原体的正常免疫识别中起着重要作用。一种变异等位基因，HLA-B（星星）57：01，与抗艾滋病毒药物阿巴卡韦过敏反应的风险增加有关。在没有遗传预筛选的情况下，超敏反应影响了6%的患者，重复给药可能危及生命。我们提供了基于HLA-B基因型的阿巴卡韦使用建议（在http://www.pharmkgb.org定期更新）。
Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B(star)57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects similar to 6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.